## **IN THE CLAIMS**

- 1-37. (canceled)
- 38. (currently amended) An expression cassette comprising a polynucleotide comprising a sequence encoding an Env polypeptide and having at least 90% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120.

39-77. (canceled)

- 78. (currently amended) A method of generating an immune response in a subject, comprising introducing an expression cassette comprising a polynucleotide comprising a sequence encoding an Env polypeptide and having at least 90% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120 into said subject under conditions that are compatible with expression of said expression cassette in said subject.
- 79. (previously presented) The method of claim 78, wherein said expression cassette is introduced using a gene delivery vector.
- 80. (previously presented) The method of claim 79, wherein the gene delivery vector is a non-viral vector.
- 81. (previously presented) The method of claim 79, wherein said gene delivery vector is a viral vector.
- 82. (previously presented) The method of claim 79, wherein said gene delivery vector is selected from the group consisting of an adenoviral vector, a vaccinia viral vector, an AAV vector, a retroviral vector, a lentiviral vector and an alphaviral vector.
- 83. (previously presented) The method of claim 82, wherein said gene delivery vector is a Sindbis-virus derived vector.

- 84. (previously presented) The method of claim 82, wherein said gene delivery vector is a cDNA vector.
- 85. (previously presented) The method of claim 82, wherein said gene delivery vector is a eukaryotic layered viral initiation system (ELVIS).
- 86. (currently amended) The method of claim 79, wherein said composition is delivered using a particulate carrier.
- 87. (previously presented) The method of claim 79, wherein said composition is coated on a gold or tungsten particle and said coated particle is delivered to said subject using a gene gun.
- 88. (previously presented) The method of claim 79, wherein said composition is encapsulated in a liposome preparation.
- 89. (previously presented) The method of claim 79, wherein said subject is a mammal.
- 90. (previously presented) The method of claim 89, wherein said mammal is a human.

## 91-97. (canceled)

- 98. (currently amended) The expression cassette of claim 38 wherein the sequence has at least 95% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120.
- 99. (currently amended) The expression cassette of claim 38 wherein the sequence has at least 98% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120.

- 100. (previously presented) The expression cassette of claim 38 wherein the sequence comprises the nucleotide sequence SEQ ID NO:120.
- 101. (currently amended) The method of claim 78 wherein the sequence has at least 95% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120.
- 102. (currently amended) The method of claim 78 wherein the sequence has at least 98% percent identity to the full-length sequence of the nucleotide sequence SEQ ID NO:120.
- 103. (previously presented) The method of claim 78 wherein the sequence comprises the nucleotide sequence SEQ ID NO:120.